March 20, 2003
Medicure To Present At Wall Street Transcript's "Investing In Healthcare" Conference
WINNIPEG, MANITOBA
(March 20, 2003) - Medicure Inc.
(TSX: MPH), a cardiovascular biotechnology company, announced today
it will be presenting at the "Investing In Healthcare"
Conference hosted by The Wall Street Transcript in New York City
on March 25, 2003. Dr. Albert D. Friesen, Medicure's
Chairman, President and Chief Executive Officer will
provide attendees with a full corporate overview and update on recent
events and activities.
"Investing
In Healthcare" is a one-day conference for securities analysts
from USA and New York based brokerage firms and investment banks,
portfolio managers from pension funds, mutual funds and trusts,
venture capitalists, institutional private equity investors, angel
investors and the financial and trade press. The event will provide
members of the US-based investment community and media an opportunity
to meet CEOs and senior executives and discuss their companies and
the progress they are making.
"We are
delighted to be presenting the Medicure story at The Wall Street
Transcript's conference, especially to such a strong and diverse
audience," Dr. Friesen stated. "This is an excellent opportunity
for us to enhance our visibility in the US financial marketplace
and make more people aware of Medicure
and our strong drug development program."
The Medicure
presentation at the Wall Street Transcript Conference is a prelude
to the Company's involvement in the American College of Cardiologists
Conference and Scientific Session, March 30 to April 2 in Chicago.
Here, Medicure, in conjunction
with The Duke Clinical Research Institute will release the full
data and complete results from its successful MEND-1 Phase II clinical
trial. In January, the Company announced positive preliminary results
with treatment from its lead compound MC-1
in the recently completed clinical study managed by the Duke Clinical
Research Institute.
"As we
stated in January, the results from this clinical trial met and
exceeded our expectations," added Dr. Friesen. "They showed
that MC-1 reduces ischemic heart
damage following angioplasty and demonstrated MC-1's
potential to be an effective drug for the treatment of ischemia
and ischemic reperfusion injury. We are very much looking forward
to presenting the full results and data from our Phase II study
at the ACC Conference."
The Phase II
trial was an investigation of the cardioprotective effects of MC-1
in mitigating damage caused by ischemia and ischemic
reperfusion in heart disease patients undergoing angioplasty.
Brokers, analysts
and portfolio managers who wish to attend the conference or learn
more about the event should contact The Wall Street Transcript at
212-852-7400, or visit the conference website at www.twst.com/conferences/gateway/healthcare.html.
About Medicure
Inc.
Medicure Inc. is a cardiovascular
drug discovery and development Company focused on developing effective
therapeutics for unmet needs in the field of cardiovascular medicine
including the prevention and treatment of ischemia, ischemic reperfusion
injury, and stroke.
This press release
contains forward-looking statements that involve risks, which may
cause actual results to differ materially from the statements made,
and accordingly may be deemed to be forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. The forward-looking statements are
made as of the date hereof, and the Company disclaims any intention
and has no obligation or responsibility to update or revise any
forward-looking statements, whether as a result of new information,
future events, or otherwise.
For more information, please contact:
Don Bain
Director of Investor & Public Relations
Medicure Inc.
Tel. 888-435-2220/Fax 204-488-9823
info@medicure.com
Back to 2003 News Archives
|
